自闭症和 adhd 的跨障碍罕见变异分析

IF 6.1 2区 医学 Q1 CLINICAL NEUROLOGY
Jinjie Duan , Jakob Grove , Ditte Demontis , F. Kyle Satterstrom , Jack Fu , Caitlin Carey , Stephan Sanders , Bernie Devlin , Kathryn Roeder , Joseph Buxbaum , Elise Robinson , Michael Talkowski , Benjamin Neale , Mark Daly , Anders Børglum
{"title":"自闭症和 adhd 的跨障碍罕见变异分析","authors":"Jinjie Duan ,&nbsp;Jakob Grove ,&nbsp;Ditte Demontis ,&nbsp;F. Kyle Satterstrom ,&nbsp;Jack Fu ,&nbsp;Caitlin Carey ,&nbsp;Stephan Sanders ,&nbsp;Bernie Devlin ,&nbsp;Kathryn Roeder ,&nbsp;Joseph Buxbaum ,&nbsp;Elise Robinson ,&nbsp;Michael Talkowski ,&nbsp;Benjamin Neale ,&nbsp;Mark Daly ,&nbsp;Anders Børglum","doi":"10.1016/j.euroneuro.2024.08.047","DOIUrl":null,"url":null,"abstract":"<div><div>Autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) are heterogeneous neurodevelopmental disorders with high heritability and frequent co-occurrence. Our previous work on the first phase of iPSYCH exomes (Satterstrom et al., 2019) suggested a similar burden of rare protein-truncating variants (PTVs) across ASD and ADHD and identified MAP1A as a shared risk gene implicated by rare PTVs in both disorders. This study aims to 1) extend these findings, employing a significantly larger iPSYCH exome dataset for gene discovery, 2) estimate the burden heritability explained by rare coding variants in ASD and ADHD, and 3) assess the burden genetic correlation between the two disorders.</div><div>We analyzed exomes of 25,208 individuals from iPSYCH, encompassing 7,119 individuals diagnosed with ASD alone (ASD-only), 5,598 with ADHD alone (ADHD-only), 3,794 with both ASD and ADHD (ASD+ADHD), and 8,697 controls. We used multivariate Poisson regression models to systematically evaluate rare variant burdens in different gene sets across the three case groups and controls, stratified further by the presence or absence of intellectual disability (ID). The gene sets included all genes, genes intolerant to loss-of-function variants (pLI &gt; 0.9), and gene sets associated with different disorders including ID, ASD, ADHD, schizophrenia, and a broader group of neurodevelopmental disorders. We applied c-alpha tests to assess whether the distribution of rare deleterious variants differs between ASD and ADHD. We employed burden heritability regression to estimate the burden heritability of ASD and ADHD, respectively, and the burden genetic correlation between the two disorders. For gene discovery, we combined individuals diagnosed with ASD and/or ADHD into a single case group and applied TADA+ to integrate with family data and Swedish PAGES case-control data from a recent large-scale ASD rare variant study (Fu et al., 2022).</div><div>We observed similar burdens of class I variants including rare PTVs and rare deleterious missense variants (MPC &gt; 3) in constrained genes across the three case groups, while they all showed a significant excess compared to controls: OR = 1.35, 95% CI = [1.26, 1.45] for ASD-only; OR = 1.35, CI = [1.25, 1.45] for ADHD-only; and OR = 1.39, CI = [1.28, 1.52] for ASD+ADHD. The c-alpha tests indicated no significant differences in the distribution of class I variants in constrained genes between ASD-only and ADHD-only groups (P= 0.39) while, when comparing the case groups to controls, significant differences were observed. The burden heritability of class I variants on the liability scale was estimated to 1.87% (SE = 0.51%) for ASD and 2.42% (s.e. = 0.72%) for ADHD. The class I variant burden genetic correlation between ASD and ADHD was 0.31 (s.e. = 0.26), which approximates the point estimate of their common-variant genetic correlation of 0.42 (s.e. = 0.05) (Demontis et al., 2023).</div><div>Our findings suggest substantial sharing of rare variant risk between ASD and ADHD, reinforcing the results of our earlier work (Satterstrom et al., 2019). This motivated us to merge individuals diagnosed with ASD and/or ADHD into a single group to enhance the discovery of rare variant risk genes shared between the disorders. This gene discovery analysis is ongoing, and the results will be presented at the conference.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"87 ","pages":"Page 17"},"PeriodicalIF":6.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CROSS-DISORDER RARE VARIANT ANALYSIS OF AUTISM AND ADHD\",\"authors\":\"Jinjie Duan ,&nbsp;Jakob Grove ,&nbsp;Ditte Demontis ,&nbsp;F. Kyle Satterstrom ,&nbsp;Jack Fu ,&nbsp;Caitlin Carey ,&nbsp;Stephan Sanders ,&nbsp;Bernie Devlin ,&nbsp;Kathryn Roeder ,&nbsp;Joseph Buxbaum ,&nbsp;Elise Robinson ,&nbsp;Michael Talkowski ,&nbsp;Benjamin Neale ,&nbsp;Mark Daly ,&nbsp;Anders Børglum\",\"doi\":\"10.1016/j.euroneuro.2024.08.047\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) are heterogeneous neurodevelopmental disorders with high heritability and frequent co-occurrence. Our previous work on the first phase of iPSYCH exomes (Satterstrom et al., 2019) suggested a similar burden of rare protein-truncating variants (PTVs) across ASD and ADHD and identified MAP1A as a shared risk gene implicated by rare PTVs in both disorders. This study aims to 1) extend these findings, employing a significantly larger iPSYCH exome dataset for gene discovery, 2) estimate the burden heritability explained by rare coding variants in ASD and ADHD, and 3) assess the burden genetic correlation between the two disorders.</div><div>We analyzed exomes of 25,208 individuals from iPSYCH, encompassing 7,119 individuals diagnosed with ASD alone (ASD-only), 5,598 with ADHD alone (ADHD-only), 3,794 with both ASD and ADHD (ASD+ADHD), and 8,697 controls. We used multivariate Poisson regression models to systematically evaluate rare variant burdens in different gene sets across the three case groups and controls, stratified further by the presence or absence of intellectual disability (ID). The gene sets included all genes, genes intolerant to loss-of-function variants (pLI &gt; 0.9), and gene sets associated with different disorders including ID, ASD, ADHD, schizophrenia, and a broader group of neurodevelopmental disorders. We applied c-alpha tests to assess whether the distribution of rare deleterious variants differs between ASD and ADHD. We employed burden heritability regression to estimate the burden heritability of ASD and ADHD, respectively, and the burden genetic correlation between the two disorders. For gene discovery, we combined individuals diagnosed with ASD and/or ADHD into a single case group and applied TADA+ to integrate with family data and Swedish PAGES case-control data from a recent large-scale ASD rare variant study (Fu et al., 2022).</div><div>We observed similar burdens of class I variants including rare PTVs and rare deleterious missense variants (MPC &gt; 3) in constrained genes across the three case groups, while they all showed a significant excess compared to controls: OR = 1.35, 95% CI = [1.26, 1.45] for ASD-only; OR = 1.35, CI = [1.25, 1.45] for ADHD-only; and OR = 1.39, CI = [1.28, 1.52] for ASD+ADHD. The c-alpha tests indicated no significant differences in the distribution of class I variants in constrained genes between ASD-only and ADHD-only groups (P= 0.39) while, when comparing the case groups to controls, significant differences were observed. The burden heritability of class I variants on the liability scale was estimated to 1.87% (SE = 0.51%) for ASD and 2.42% (s.e. = 0.72%) for ADHD. The class I variant burden genetic correlation between ASD and ADHD was 0.31 (s.e. = 0.26), which approximates the point estimate of their common-variant genetic correlation of 0.42 (s.e. = 0.05) (Demontis et al., 2023).</div><div>Our findings suggest substantial sharing of rare variant risk between ASD and ADHD, reinforcing the results of our earlier work (Satterstrom et al., 2019). This motivated us to merge individuals diagnosed with ASD and/or ADHD into a single group to enhance the discovery of rare variant risk genes shared between the disorders. This gene discovery analysis is ongoing, and the results will be presented at the conference.</div></div>\",\"PeriodicalId\":12049,\"journal\":{\"name\":\"European Neuropsychopharmacology\",\"volume\":\"87 \",\"pages\":\"Page 17\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Neuropsychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0924977X24002463\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924977X24002463","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

自闭症谱系障碍(ASD)和注意缺陷多动障碍(ADHD)是异质性神经发育疾病,具有高遗传性和频繁并发性。我们之前对第一阶段 iPSYCH 外显子的研究(Satterstrom 等人,2019 年)表明,自闭症谱系障碍(ASD)和注意力缺陷多动障碍(ADHD)中存在相似的罕见蛋白质截断变异(PTVs),并发现 MAP1A 是这两种疾病中罕见 PTVs 所涉及的共同风险基因。本研究旨在:1)扩展这些发现,利用更大的 iPSYCH 外显子组数据集来发现基因;2)估计 ASD 和 ADHD 中罕见编码变异所解释的负荷遗传率;3)评估这两种疾病之间的负荷遗传相关性。我们分析了来自 iPSYCH 的 25208 个个体的外显子组,其中包括 7119 个单独诊断为 ASD 的个体(ASD-only)、5598 个单独诊断为 ADHD 的个体(ADHD-only)、3794 个同时诊断为 ASD 和 ADHD 的个体(ASD+ADHD)以及 8697 个对照组。我们使用多变量泊松回归模型系统地评估了三个病例组和对照组中不同基因组的罕见变异负担,并根据是否存在智力障碍(ID)进行了进一步分层。基因集包括所有基因、不耐受功能缺失变异的基因(pLI > 0.9),以及与不同疾病相关的基因集,包括ID、ASD、ADHD、精神分裂症和更广泛的神经发育障碍。我们采用c-α检验来评估ASD和ADHD之间罕见有害变异的分布是否存在差异。我们采用负荷遗传率回归法分别估算了 ASD 和 ADHD 的负荷遗传率,以及这两种疾病之间的负荷遗传相关性。为了发现基因,我们将确诊为ASD和/或ADHD的个体合并为一个病例组,并应用TADA+与最近一项大规模ASD罕见变异研究(Fu等人,2022年)中的家族数据和瑞典PAGES病例对照数据进行整合。我们在三个病例组的受限基因中观察到了相似的I类变异负担,包括罕见的PTV和罕见的致畸性错义变异(MPC >3),而与对照组相比,它们都显示出显著的过量:仅 ASD 的 OR = 1.35,95% CI = [1.26,1.45];仅 ADHD 的 OR = 1.35,CI = [1.25,1.45];ASD+ADHD 的 OR = 1.39,CI = [1.28,1.52]。c-α检验表明,纯ASD组和纯ADHD组之间受限基因中I类变异的分布无显著差异(P= 0.39),而当病例组与对照组比较时,则观察到显著差异。据估计,ASD 和 ADHD 的 I 类变异在责任量表上的负担遗传率分别为 1.87%(SE = 0.51%)和 2.42%(s.e. = 0.72%)。ASD和ADHD之间的I类变异负担遗传相关性为0.31(s.e. = 0.26),近似于其共同变异遗传相关性的点估计值0.42(s.e. = 0.05)(Demontis等人,2023年)。这促使我们将被诊断为 ASD 和/或 ADHD 的个体合并为一个群体,以促进发现这两种疾病之间共享的罕见变异风险基因。这项基因发现分析正在进行中,结果将在大会上公布。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
CROSS-DISORDER RARE VARIANT ANALYSIS OF AUTISM AND ADHD
Autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) are heterogeneous neurodevelopmental disorders with high heritability and frequent co-occurrence. Our previous work on the first phase of iPSYCH exomes (Satterstrom et al., 2019) suggested a similar burden of rare protein-truncating variants (PTVs) across ASD and ADHD and identified MAP1A as a shared risk gene implicated by rare PTVs in both disorders. This study aims to 1) extend these findings, employing a significantly larger iPSYCH exome dataset for gene discovery, 2) estimate the burden heritability explained by rare coding variants in ASD and ADHD, and 3) assess the burden genetic correlation between the two disorders.
We analyzed exomes of 25,208 individuals from iPSYCH, encompassing 7,119 individuals diagnosed with ASD alone (ASD-only), 5,598 with ADHD alone (ADHD-only), 3,794 with both ASD and ADHD (ASD+ADHD), and 8,697 controls. We used multivariate Poisson regression models to systematically evaluate rare variant burdens in different gene sets across the three case groups and controls, stratified further by the presence or absence of intellectual disability (ID). The gene sets included all genes, genes intolerant to loss-of-function variants (pLI > 0.9), and gene sets associated with different disorders including ID, ASD, ADHD, schizophrenia, and a broader group of neurodevelopmental disorders. We applied c-alpha tests to assess whether the distribution of rare deleterious variants differs between ASD and ADHD. We employed burden heritability regression to estimate the burden heritability of ASD and ADHD, respectively, and the burden genetic correlation between the two disorders. For gene discovery, we combined individuals diagnosed with ASD and/or ADHD into a single case group and applied TADA+ to integrate with family data and Swedish PAGES case-control data from a recent large-scale ASD rare variant study (Fu et al., 2022).
We observed similar burdens of class I variants including rare PTVs and rare deleterious missense variants (MPC > 3) in constrained genes across the three case groups, while they all showed a significant excess compared to controls: OR = 1.35, 95% CI = [1.26, 1.45] for ASD-only; OR = 1.35, CI = [1.25, 1.45] for ADHD-only; and OR = 1.39, CI = [1.28, 1.52] for ASD+ADHD. The c-alpha tests indicated no significant differences in the distribution of class I variants in constrained genes between ASD-only and ADHD-only groups (P= 0.39) while, when comparing the case groups to controls, significant differences were observed. The burden heritability of class I variants on the liability scale was estimated to 1.87% (SE = 0.51%) for ASD and 2.42% (s.e. = 0.72%) for ADHD. The class I variant burden genetic correlation between ASD and ADHD was 0.31 (s.e. = 0.26), which approximates the point estimate of their common-variant genetic correlation of 0.42 (s.e. = 0.05) (Demontis et al., 2023).
Our findings suggest substantial sharing of rare variant risk between ASD and ADHD, reinforcing the results of our earlier work (Satterstrom et al., 2019). This motivated us to merge individuals diagnosed with ASD and/or ADHD into a single group to enhance the discovery of rare variant risk genes shared between the disorders. This gene discovery analysis is ongoing, and the results will be presented at the conference.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
European Neuropsychopharmacology
European Neuropsychopharmacology 医学-精神病学
CiteScore
10.30
自引率
5.40%
发文量
730
审稿时长
41 days
期刊介绍: European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信